A 50-year-old woman was referred to our emergency room because of urticaria. Eleven days after etanercept therapy was started, the patient developed an urticarial rash of the trunk and face. A diagnosis of generalized urticaria was made. Etanercept treatment was suspended. Treatment was started with methylprednisolone and dexchlorpheniramine. The patient's condition improved and she was discharged. In this case, the most probable cause of urticaria was considered to be etanercept because of the temporal relationship between exposure to the drug and the onset of symptoms. The adverse reaction could be considered probable. Although the overall risk of skin adverse events associated with etanercept appears low, clinicians should be aware of this reaction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SMJ.0b013e31819450e7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The relationship between drug-induced immunogenicity and hypersensitivity reactions and skin tests related to infliximab, etanercept and adalimumab in patients with rheumatoid arthritis and ankylosing spondylitis.
Turk J Med Sci
December 2024
Division of Clinical Immunology and Allergy, Department of Chest Diseases, Faculty of Medicine, Ankara University, Ankara, Turkiye.
Article Synopsis
- The study aimed to explore the connection between serum antidrug antibodies (ADAbs), hypersensitivity reactions, and local injection site reactions in patients with ankylosing spondylitis and rheumatoid arthritis who were on anti-TNF treatments.
- Sixty-nine patients with ankylosing spondylitis and 46 with rheumatoid arthritis were evaluated, measuring their drug levels, disease activity scores, and conducting skin tests to assess hypersensitivity.
- Results indicated a significant link between hypersensitivity reactions (both immediate and local) and the intradermal tests in patients taking anti-TNF drugs, particularly with adalimumab and etanercept.
Anti-TNF-α induced mucous membrane pemphigoid-like disease.
Oral Surg Oral Med Oral Pathol Oral Radiol
November 2024
Department of Surgical, Medical, Dental, and Morphological Science, University of Modena and Reggio Emilia, Modena, Italy.
Article Synopsis
- Mucous membrane pemphigoid (MMP) is an autoimmune disease that causes blistering mainly in mucous membranes, with rare cases affecting the skin; a case study highlighted the impact of the drug etanercept on MMP-like symptoms in a 40-year-old woman.* -
- The symptoms, including recurring desquamative gingivitis, were linked to the timing of drug treatment, with flare-ups occurring when the drug was resumed and improvement when it was stopped, supported by laboratory findings.* -
- The case identifies a possible adverse drug reaction and discusses the significance of TNF-α in the condition's mechanism, emphasizing the complexity of autoimmune disorders, medication interactions, and external influences like viral infections like
Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs.
BMC Pharmacol Toxicol
October 2021
Research Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany.
Background: Adverse drug reactions (ADRs) in the pediatric population may differ in types and frequencies compared to other populations. Respective studies analyzing ADR reports referring to children have already been performed for certain countries. However, differences in drug prescriptions, among others, complicate the transferability of the results from other countries to Germany or were rarely considered.
View Article and Find Full Text PDFTwo Cases of Cutaneous Adverse Effects Induced by Tumor Necrosis Factor-Alpha Inhibitors.
Case Rep Dermatol
April 2021
Department of Dermatology, Graduate School of Medicine, Mie University, Tsu, Japan.
Here, we report two cases of cutaneous adverse effects possibly induced by the use of tumor necrosis factor-alpha (TNF-α) inhibitors. The first case presented alopecia areata (AA) and atopic dermatitis (AD) that developed during the treatment of ulcerative colitis using infliximab; the other case presented urticaria and AD that developed during the treatment of rheumatoid arthritis using etanercept. AA, AD, and urticaria are relatively common skin diseases; however, they are not well known as adverse effects of TNF-α inhibitors.
View Article and Find Full Text PDF[SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Pan Afr Med J
November 2020
Service de Rhumatologie, Centre Hospitalier Universitaire Mohamed VI, Marrakech, Maroc.
Hydroxychloroquine is an agent used as a treatment but also considered as a prophylaxis for SARS-CoV-2 infection. We report the case of a patient who developed COVID-19 while on hydroxychloroquine for mixed connectivitis associated with spondyloarthritis. Although more work is needed before any conclusions can be drawn, this raises questions about the protective role of this drug against infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!